Epidermal Growth Factor Receptor human
SIGMA/E2645 - lyophilized powder, ≥15,000 units/mg protein (Bradford)
Synonym: ERBB; ErbB1; HER1; EGFR
MDL Number: MFCD01634808
Product Type: Chemical
SDS-PAGE Epidermal Growth Factor Receptor Human (Cat. No. E2645) was assessed on SDS-PAGE.
Epidermal
Growth Factor Receptor (EGFR) Pathway Research areas:
Cancer biology, Cell proliferation, Metabolism. Disease areas:
Breast, lung, stomach, gastrointestinal cancers, chronic kidney diseases,
glioblastomas.
| biological source | human |
| color | white |
| form | lyophilized powder |
| mol wt | ~170 kDa |
| packaging | pkg of 500UN |
| potency | >15000.00 units/mg |
| Quality Level | 300  |
| shipped in | dry ice |
| solubility | glycerol: 10%, clear to slightly hazy, colorless |
| specific activity | ≥15,000 units/mg protein (Bradford) |
| storage condition | avoid repeated freeze/thaw cycles |
| storage temp. | −20°C |
| technique(s) | cell based assay: suitable |
| UniProt accession no. | P00533  |
| Biochem/physiol Actions: | 170 kDa glycoprotein having EGF-activated protein tyrosine kinase activity; high levels of EGFR are expressed in approximately one third of human epithelial tumors, and in the cancers of the bladder, breast or lung that have poor clinical prognosis. |
| Biochem/physiol Actions: | EGF exerts its actions by binding to the EGF receptor (EGFR), a 170 kDa glycoprotein having EGF-activated protein tyrosine kinase activity. Even in the absence of EGF-like ligands, EGFR can participate in cellular responses elicited by several other stimuli. High levels of EGFR are expressed in approximately one third of human epithelial tumors, and in the cancers of the bladder, breast or lung that have poor clinical prognosis, hence the interest in targeting EGFR. |
| Biochem/physiol Actions: | Epidermal growth factor receptor (EGFR) has an essential role in normal developmental processes, and is mutated in multiple cancers. It is involved in the pathogenesis of epidermoid tumors, and thus, has extreme importance as a cancer therapeutic target. Gefitinib (GEF) and erlotinib act as EGFR inhibitors, and induce apoptosis in non-small cell lung cancer (NSCLC) cells. A truncated isoform, called EGFRvIII is linked to multiple cases of head and neck squamous cell carcinoma (HNSCC). In ∼40% of glioblastoma multiforme (GBM), this gene is amplified. |
| General description: | Research area: Cell signaling Epidermal growth factor receptor (EGFR) belongs to a family of cell surface receptors called receptor tyrosine kinases (RTKs) and is also the most studied member of this family. The EGFR is encoded by the ErbB gene, mapped to chromosome 7 q22. These receptors are attached to the cytoplasmic membrane and consist of an ectodomain (ECD), comprising of four subdomains called DI-DIV, a hydrophobic transmembrane domain, and an intracytoplasmic tyrosine kinase domain. |
| Other Notes: | One unit (U) of the enzyme is defined as the amount needed to incorporate 1 pmol of phosphate into the substrate (KVEKIGEGTYGVVYK: 6 - 20 residue of p34cdc2) in 1 minute. |
| Physical form: | Lyophilized from a solution in 50 mM HEPES, pH 7.6, 150 mM NaCl, 0.05% Triton X-100, 1 mM dithiothreitol, and 10% trehalose. |
| Preparation Note: | Affinity purified from human carcinoma A431 cells. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| activity | specific activity: ≥15,000 units/mg protein (Bradford) |
| Storage Temp. | −20°C |
| UNSPSC | 12352202 |